Panic disorder and social phobia: Current treatments and new strategies

Cleveland Clinic Journal of Medicine

Volumn 65, Issue SUPPL.1, 1998, Pages

  Davidson, Jonathan R T ^a   Connor, Kathryn M ^a   Sutherland, Suzanne M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID DERIVATIVE; AMINE; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; GABAPENTIN; SEROTONIN UPTAKE INHIBITOR;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PANIC; PHOBIA; REVIEW;

ACETIC ACIDS; AMINES; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; PANIC DISORDER; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 0008000918     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.s1.39     Document Type: Article

References (39)

1. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996; 53:159-168.
2. Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J. Costs and offset effect in panic patients. Br J Psychiatry 1995; 27(suppl):23-28.
3. Mavossakalian M, Perel J. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992; 49:318-323.
4. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964; 5:397-408.
5. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a doseresponse study of efficacy, safety, and discontinuance. J Clin Psychopharmacol 1997; 17:390-400.
6. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150:1485-1490.
7. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994; 151:876-881.
8. Paxil (paroxetine hydrochloride) prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc; 1998:2851-2856.
9. Zoloft (sertraline hydrochloride) prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc; 1998:2229-2234.
10. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10:119-121.
11. Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329-332.
12. Bakish D, Hooper CL, Filteau MJ, et al. A double-blind placebo- controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32:135-141.
13. Van Vliet IM, den Boer JA, Westenberg HG, Slaap BR. A double- blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 1996; 16:299-306.
14. Spiegel DA, Saeed SA, Bruce TJ. An open trial of fluvoxamine therapy for panic disorder complicated by depression. J Clin Psychiatry 1996; 57(suppl 8):37-41.
15. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dosed, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155:36-42.
16. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95:153-160.
17. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo- controlled study. Br J Psychiatry 1995; 167:374-379.
18. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155:1189-1195.
19. Lum M, Fontaine R, Elie R, Ontiveros A. Probable interaction of sodium divalproex with benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15:269-273.
20. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55:134-136.
21. Keck PE Jr, Taylor VE, Tugrul KC, McElroy SL, Bennet JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33:542-546.
22. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12- month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
23. Heinberg RG, Liebowitz MR, Hope DA, et al. Cognitivebehavioral group therapy versus phenelzine in social phobia: 12- week outcome. Arch Gen Psychiatry. In press.
24. Liebowitz MR, Schneier FR, Campeas R, et al. Phenelzine vs. atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290-300.
25. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-60.
26. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia- a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71-80.
27. Noyes R, Moroz G, Davidson JRT, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17:245-54.
28. Davidson JRT, Potts NLS, Richichi EA, Krishnan KRR, Ford SM, Smith RD, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423-428.
29. Berk M. Fluoxetine and social phobia [letter]. J Clin Psychiatry 1995; 56:36-37.
30. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [letter]. J Clin Psychopharmacol 1992; 12:293-295.
31. Ringold AL. Paroxetine efficacy in social phobia [letter]. J Clin Psychiatry 1994; 55:363-364.
32. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992; 12:62-64-
33. Sternback H. Fluoxetine treatment of social phobia [letter]. J Clin Psychopharmacol 1990; 10:230-231.
34. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993; 54:27-32.
35. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind, placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16:218-222.
36. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708-713.
37. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371.
38. Van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a doubleblind, placebo-controlled study with fluvoxamine. Psychopharmacology (Beri) 1994; 115:128-134.
39. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. In press 1998.